AI and Machine Learning in Clinical Trial Imaging: Transforming Data Analysis and Decision-Making
The global clinical trial imaging market size is expected to reach USD 1.91 billion by 2030, registering a CAGR of 7.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing research and development spending to discover new drugs and therapies to treat chronic diseases is propelling the industry growth. Images obtained from the internal examination of the body are used to determine drug activity. Clinical trial imaging provides rapid, detailed, and accurate screening. The need for clinical trial imaging is rapidly increasing in all phases of trials. Medical imaging in clinical trials is used as a primary, quantitative, and surrogate biomarker.
The clinical trial design includes selecting patient population, stratification based on biomarkers, different methods for allocation treatments, choosing efficient and reliable endpoints and validation of surrogate endpoints, calculating sample size, trial simulations, adaptive trial set-up, statistical and interim analysis, and assisting clients to deal with regulatory authorities such as EMA and FDA to discuss study design or defend study results.
Market players provide analytical testing services, pharmacokinetic, reading, and pharmacodynamics services for enhanced clinical development. IXICO offers advanced technologies for catalyzing clinical trials in neuroscience. Imaging biomarkers by the company help in measuring the safety and effectiveness of therapies used for neuro-imaging. Imaging biomarkers are effective in radiological reads. This provides the reading of MRI scans for central neuro to enhance the assessment of ongoing monitoring of drug safety and subject eligibility
Clinical Trial Imaging Market Report Highlights
- The reading and analytical services segment held the largest market share at 30.95% in 2024 and is expected to grow at a CAGR of 8.4% from 2025 to 2030, highlighting its critical role in ensuring the accuracy and reliability of imaging data in clinical research.
- The biotechnology and pharmaceutical companies segment accounted for the largest share of 28.7% in 2024. The factor attributing to the dominance of this segment is the need to develop new drugs and therapies to cure chronic diseases.
- Oncology segment held the largest market share of 23.63% in 2024. High prevalence of cancer cases and the constant need for new and innovative therapies to treat various types of cancer are expected to fuel the market growth.
- The contract research organizations (CROs) segment is expected to grow significantly with a CAGR of 8.5% over the forecast period, owing to its essential role in developing new drugs and therapies for chronic diseases.
- North America dominated the market with a revenue share of 47.93% in 2024 due to the increasing geriatric population, along with chronic diseases and growing demand for treatment options.
Clinical Trial Imaging Market Segmentation
Grand View Research has segmented the global clinical trial imaging market based on modality, therapeutic area, services, end use and region:
Clinical Trial Imaging Modality Outlook (Revenue, USD Million, 2018 - 2030)
- Computed Tomography Scan
- Magnetic Resonance Imaging
- X-Ray
- Ultrasound
- Optical Coherence Tomography (OCT)
- Other Modalities
Clinical Trial Imaging Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
- Neurovascular Diseases
- Cardiovascular Diseases
- Orthopedics & MSK Disorders
- Oncology
- Ophthalmology
- Nephrology
- Other Therapeutic Areas
Clinical Trial Imaging Services Outlook (Revenue, USD Million, 2018 - 2030)
- Clinical Trial Design and Consultation Services
- Reading and Analytical Services
- Operational Imaging Services
- System and Technology Support Services
- Project and Data Management
Clinical Trial Imaging End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Biotechnology and Pharmaceutical Companies
- Medical Devices Manufacturers
- Academic and Government Research Institutes
- Contract Research Organizations (CROs)
- Other End Users
Clinical Trial Imaging Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- US
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- India
- China
- Japan
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Key Players
- IXICO plc
- Navitas Life Sciences
- Resonance Health
- ProScan Imaging
- Radiant Sage LLC
- Medpace
- Biomedical Systems Corp
- Cardiovascular Imaging Technologies
- Intrinsic Imaging
- BioTelemetry
Order a free sample PDF of the Clinical Trial Imaging Market Intelligence Study, published by Grand View Research.
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Games
- Gardening
- Health
- Home
- Literature
- Music
- Networking
- Other
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness
- IT, Cloud, Software and Technology
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian